%0 Journal Article
%A Colhoun, Helen M
%A Leiter, Lawrence A
%A Müller-Wieland, Dirk
%A Cariou, Bertrand
%A Ray, Kausik K
%A Tinahones, Francisco J
%A Domenger, Catherine
%A Letierce, Alexia
%A Israel, Marc
%A Samuel, Rita
%A Del Prato, Stefano
%T Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
%D 2020
%U http://hdl.handle.net/10668/15076
%X Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that effectively reduces low-density lipoprotein cholesterol (LDL-C), non-HDL-C, ApoB, and lipoprotein(a) (Lp[a]), and is well-tolerated in individuals with T2DM. The previously reported open-label ODYSSEY DM-DYSLIPIDEMIA trial data demonstrated the effects of alirocumab on individuals with non-HDL-C ≥ 100 mg/dL and TGs ≥ 150 and  Alirocumab significantly reduced non-HDL-C [LS mean difference (standard error (SE)), - 35.0% (3.9)], ApoB [LS mean difference (SE), - 34.7% (3.6)], LDL-C [LS mean difference (SE), - 47.3% (5.2)], LDL particle number [LS mean difference (SE), - 40.8% (4.1)], and Lp(a) [LS mean difference (SE), - 29.9% (5.4)] versus usual care from baseline to Week 24 (all P  Alirocumab is an effective therapeutic option for individuals with T2DM, TGs ≥ 200 mg/dL, and HDL-C 
%K Alirocumab
%K DM-DYSLIPIDEMIA
%K Diabetes mellitus
%K HDL-C
%K Non-HDL-C
%K ODYSSEY
%K PCSK9
%K Triglycerides
%K Type 2 diabetes
%K Usual care
%~